<DOC>
	<DOC>NCT03010046</DOC>
	<brief_summary>This is a single-center, randomized, double-blind, placebo-controlled, ascending, single-infusion, sequential group study. Single, ascending doses will be administered to approximately 56 subjects, with an option for 1 additional multi-dose cohort in approximately 8 subjects. The primary objective is to evaluate the safety of ANX005 administered as an intravenous infusion as a single agent and in combination with intravenous immunoglobulin (IVIg). The optional multi-dose cohort will evaluate either additional subjects at the maximum tolerated dose or ANX005 administered as 2 infusions.</brief_summary>
	<brief_title>Single Dose Study of ANX005 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<criteria>Male and females 18 years and older Females must be postmenopausal, surgically sterilized, or willing and able to use 2 methods of contraception throughout the study and for 1 month after the final study visit Willing and able to undergo vaccination if not vaccinated recently History of any autoimmune disease, meningitis, septicemia or pneumonia History of hypercoagulable diseases, hyperviscosity, thrombosis, renal dysfunction or acute renal failure Known genetic deficiencies of the complement cascade system History of conditions whose symptoms and effects could alter protein catabolism or IgG utilization, e.g. proteinlosing enteropathies or nephrotic syndrome Body weight less than 50 kg or greater than 100 kg Hypersensitivity or allergic reactions to any excipients in the ANX005 drug product (Cohorts 4b and 5b) Known selective IgA deficiency or presence of antibodies to IgA at screening (Cohorts 4b and 5b) Prior reaction or hypersensitivity to blood products, including IVIg or any of the excipients in IVIg.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>